Core Insights - Esperion announced the acceptance of two abstracts for presentation at the American College of Cardiology's 2026 Annual Scientific Session, focusing on Bempedoic Acid as a therapeutic option for patients needing alternatives to statins [1][2] Group 1: Presentation Details - The first presentation will analyze the incidence of stroke among statin-intolerant patients based on the CLEAR Outcomes trial, scheduled for March 28, 2026 [3] - The second presentation will focus on cardiovascular outcomes in patients with autoimmune or inflammatory diseases, scheduled for March 29, 2026 [3] Group 2: Company Overview - Esperion Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing innovative therapies for cardiometabolic and rare diseases, leveraging expertise in ACLY biology [4] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels [4] - Esperion has a broad U.S. commercial infrastructure and global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access [5]

Core Insights - Bempedoic acid has received strong endorsement from the AHA/ACC Multisociety Guideline for patients with statin intolerance and severe hypercholesterolemia, positioning it alongside PCSK9 mAb and ezetimibe for high-risk primary prevention and clinical ASCVD patients not at very high risk [1][2] - The guideline emphasizes the importance of early combination lipid-lowering therapy and reintroduces LDL-C goals, supporting the 'lower for longer is better' approach to cardiovascular risk reduction [1][5] Summary of Recommendations - Class 1 recommendations indicate that adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms and are at high ASCVD risk should add bempedoic acid and/or ezetimibe to lower LDL-C to <70 mg/dL and non-HDL-C <100 mg/dL [3] - For adults with clinical ASCVD experiencing statin-attributed muscle symptoms, a reduced statin dose and the addition of bempedoic acid, ezetimibe, or a PCSK9 mAb are recommended to lower LDL-C and reduce ASCVD risk [3] - In adults with diabetes who have statin-attributed side effects, initiation of ezetimibe and/or bempedoic acid or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk [3] - For adults with severe hypercholesterolemia on maximally tolerated statin therapy, the addition of ezetimibe, a PCSK9 mAb, and/or bempedoic acid is recommended to achieve LDL-C goals and reduce ASCVD risk [3] - Class 2a recommendations suggest that for adults with clinical ASCVD not at very high risk, it is reasonable to add bempedoic acid, ezetimibe, or a PCSK9 mAb to achieve LDL-C <70 mg/dL and non-HDL-C <100 mg/dL [3][7] Company Positioning - Esperion views the guideline recognition as a significant milestone that validates bempedoic acid as an evidence-based therapy for patients requiring additional LDL-C lowering or unable to tolerate statins, which strengthens its market position [2] - The endorsement is expected to accelerate the adoption and expand access to Esperion's products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) [2][10]

Core Insights - Esperion's bempedoic acid has been included in the 2026 ACC/AHA Multisociety Guideline for LDL-C lowering and cardiovascular risk reduction, marking a significant endorsement for the company and its products [1][2] Group 1: Guideline Recommendations - Bempedoic acid has received the strongest endorsement from AHA/ACC guidelines for patients with statin intolerance and for both primary and secondary prevention in patients with severe hypercholesterolemia [4] - The guidelines position bempedoic acid equally with PCSK9 monoclonal antibodies and ezetimibe after statins for high-risk primary prevention and clinical ASCVD patients not at very high risk [4] - The reintroduction of LDL-C goals emphasizes the 'lower for longer is better' approach to cardiovascular risk reduction, supporting earlier and more aggressive combination therapy [4][7] Group 2: Class of Recommendations - Class 1 recommendations indicate that adults without a history of clinical ASCVD who experience statin-related muscle symptoms and are at high ASCVD risk should add bempedoic acid and/or ezetimibe to lower LDL-C to <70 mg/dL [5] - In adults with clinical ASCVD experiencing statin-related muscle symptoms, the addition of bempedoic acid, ezetimibe, or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk [5] - For adults with diabetes who have statin-related side effects, initiation of ezetimibe and/or bempedoic acid or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk [5] Group 3: Company Positioning - The recognition from leading American cardiovascular medical associations strengthens Esperion's position in the treatment landscape and is expected to accelerate the adoption of NEXLETOL® and NEXLIZET® [2][4] - Esperion is well-positioned to serve as a partner for global innovators seeking U.S. market access, leveraging its commercial infrastructure and expertise in ACLY biology [12][13]

Core Insights - Esperion Therapeutics reported Q4 2025 EPS of 22 cents, missing the Zacks Consensus Estimate of 23 cents, while total revenues reached $168.4 million, a 144% year-over-year increase, surpassing the estimate of $161 million [1][7] Financial Performance - Total revenues for 2025 were $403.1 million, reflecting a 21% year-over-year growth, with a net loss of 11 cents per share for the year [10] - Product revenues from the U.S. in Q4 totaled $43.7 million, a 38% increase year-over-year, but fell short of the model estimate of $79 million [7] - Collaboration revenues surged 232% year-over-year to $124.7 million, driven by a one-time $90 million payment from Otsuka, exceeding both the Zacks Consensus Estimate and internal model estimates [7][8] Expenses - Research and development expenses increased by 26% year-over-year to $13.9 million due to higher costs in ongoing clinical studies [8] - Selling, general, and administrative expenses rose 12% year-over-year to $41.4 million, attributed to increased legal costs related to ANDA litigation [9] Recent Developments - Esperion announced the acquisition of Corstasis Therapeutics, expected to close in Q2 2026, which will add the Enbumyst nasal spray to its portfolio, targeting a market opportunity exceeding $4 billion in the U.S. [12][13][14] - A settlement agreement was reached with Alkem Laboratories and Dr. Reddy's regarding patents for Nexletol and Nexlizet, preventing the launch of generic versions before April 19, 2040, under certain conditions [15][16] Market Performance - Esperion's stock has increased by 77.6% over the past year, significantly outperforming the industry growth of 2.2% [4]

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Industry**: Cardiovascular therapeutics - **Recent Performance**: Reported earnings with significant growth metrics Key Financial Highlights - **Total Revenue**: $408 million, representing a **38% year-over-year growth** [2] - **TRx Growth**: **34% year-over-year** and **11% quarter-over-quarter** growth in TRx [2] Acquisition Details - **Acquisition of Corstasis**: - Focused on a newly approved nasal loop diuretic, Enbumyst, which is **40 times more potent than furosemide** [3][6] - Expected to close in the **first week of April 2026** [3] - **Transaction Value**: $75 million upfront plus up to $180 million in milestones [18] - Financing through expanding existing term loan and monetizing Japanese royalties [19] Market Opportunity - **Target Markets**: - Expanding into cardiometabolic field, addressing unmet needs in heart failure [6][7] - Anticipated to reduce hospital readmission rates, which cost between **$12,000-$18,000** per heart failure readmission [13] - **Nasal Delivery System**: - Easy to use, potentially improving patient compliance and outcomes [14][16] Commercial Strategy - **Integration Plans**: - Pre-integration phase ongoing, with plans to leverage existing commercial infrastructure for product launch [23] - Focus on payer access and relationships with specialty pharmacies [30] - **Growth Strategy for Bempedoic Acid**: - Targeting **$1 billion plus opportunities** in the U.S. market [37] - Emphasis on maximizing NEXLIZET and NEXLETOL products [39] Competitive Landscape - **Guidelines and Market Position**: - Anticipation of new guidelines to provide a tailwind for bempedoic acid [37] - Highlighting unique outcomes data to differentiate from competitors [40][41] International Markets - **Partnerships**: - Strong performance reported by Daiichi Sankyo in Europe, particularly in Germany and the UK [57][61] - Otsuka in Japan showing promising sales, with over **700 representatives** promoting the drug [61] Future Outlook - **Vision 2040**: - Focus on growing the bempedoic acid franchise, business development, and pipeline expansion [78] - Upcoming clinical trials for ESP-2001 targeting primary sclerosing cholangitis [79] - Plans to explore kidney-related therapies, complementing heart failure treatments [80] Financial Health - **Cash Position**: - Ended the year with **$168 million** in cash, with ongoing improvements to the balance sheet [72] - Commitment to deleveraging while maintaining growth [75] Conclusion - Esperion Therapeutics is positioned for significant growth through strategic acquisitions, a robust product pipeline, and a strong commercial strategy aimed at addressing unmet needs in cardiovascular care. The company anticipates continued success in 2026, building on the momentum from 2025.

Regulatory Approvals and Challenges - The FDA approved NEXLETOL and NEXLIZET in February 2020, with commercial availability starting in March and June 2020 respectively[216]. - NILEMDO and NUSTENDI received regulatory approval in the EU and other countries, with launches occurring in multiple regions including Turkey and Hong Kong[216]. - On March 22, 2024, the FDA approved new label expansions for NEXLETOL and NEXLIZET, including indications for cardiovascular risk reduction[216]. - The company has received approvals from various health authorities, but future approvals in other territories remain uncertain[218]. - Regulatory approvals for bempedoic acid and the combination tablet are complex and may be delayed or denied by authorities[221]. - The company has received marketing approval for bempedoic acid and the bempedoic acid/ezetimibe combination tablet in the U.S., Europe, and parts of Asia, but may face ongoing regulatory challenges and restrictions[229]. - The FDA has significant post-marketing regulatory authority, which may require additional studies and impose restrictions on the marketing and use of bempedoic acid and the combination tablet[231]. - The company may encounter significant hurdles in clinical development and regulatory processes that could adversely affect its commercialization efforts[219]. - The company faces scrutiny over patient assistance programs, which could lead to significant civil and criminal settlements if found non-compliant[252]. - The company may face challenges in obtaining favorable reimbursement for bempedoic acid in foreign markets, affecting operating results[261]. Financial Performance and Projections - In 2025, the company generated $159.6 million in net revenues from the sale of products in the U.S.[216]. - The company incurred net losses of $22.7 million, $51.7 million, and $209.2 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of $1.6 billion as of December 31, 2025[363]. - The company expects to continue incurring operating losses for the immediate future related to the commercialization of NEXLETOL and NEXLIZET, as well as ongoing research and development expenses[364]. - The company anticipates that its existing cash and cash equivalents will be sufficient to fund operations for the foreseeable future, but may need to secure additional cash resources for further development[367]. - The company may face challenges in generating sufficient cash flow to service its debt obligations[384]. Competition and Market Dynamics - The market for LDL-C and cardiovascular risk-lowering therapies is highly competitive, with potential competitors including major pharmaceutical companies and biotechnology firms[293]. - The company faces competition from inexpensive generic versions of statins and other LDL-C lowering therapies, which could adversely affect market share and revenue[296]. - The availability of generic LDL-C lowering treatments could significantly decrease reimbursement levels for branded products, affecting market acceptance and business performance[265]. - The company has received notices from nine pharmaceutical companies regarding the filing of Abbreviated New Drug Applications (ANDAs) for generic versions of NEXLETOL and NEXLIZET, which could affect sales[242]. Intellectual Property and Litigation - The company filed patent infringement lawsuits against ANDA filers to prevent the approval of generic versions of NEXLETOL and NEXLIZET before the expiration of relevant patents[245]. - Settlement agreements have been reached with several ANDA filers, preventing them from marketing generic versions of NEXLETOL and NEXLIZET in the U.S. prior to April 19, 2040[246]. - The company faces risks related to potential patent conflicts that could affect its ability to commercialize products, including the need to obtain licenses from third parties[406]. - The company’s ability to enforce patent rights is contingent on detecting infringement, which can be challenging and costly[411]. - Legal proceedings to defend patents could result in invalidation or narrow interpretation, adversely impacting the company's financial position[412]. Compliance and Regulatory Risks - The company faces potential adverse consequences from regulatory non-compliance, including fines, injunctions, and suspension of marketing approvals[232]. - The company must continue to invest in regulatory compliance, including manufacturing, production, and quality control to avoid negative impacts on its business[234]. - Non-compliance with Medicaid Drug Rebate Program (MDRP) reporting obligations may result in penalties and adversely affect financial results and growth prospects[266]. - The company is subject to the EU General Data Protection Regulation (GDPR), which imposes strict requirements on personal data processing and could increase compliance costs[273]. - The existence of various state privacy laws complicates compliance obligations and may increase the risk of enforcement actions or liability for noncompliance[281]. Research and Development - The company announced the completion of the CLEAR Outcomes CVOT in December 2022 and presented two post hoc analyses in November 2025, indicating ongoing clinical development efforts[328]. - The company may experience delays or failures in clinical trials due to various factors, including negative interim results and regulatory authority holds[329]. - The company expects its research and development expenses to remain consistent in 2026 due to ongoing clinical trials and pipeline work[364]. - The company may seek orphan drug status for its product candidate ESP-2001, which is a next-generation ACLY inhibitor, under the Orphan Drug Act of 1983[336]. Financing and Capital Structure - The company entered into a Credit Agreement providing for a $150.0 million term loan, which was fully borrowed at closing, to repay a portion of existing obligations[373]. - The Loan under the Credit Agreement bears interest at an annual rate of 9.75% if paid in cash, and 11.75% if paid-in-kind, with $9.1 million added to the principal balance due to interest payments[375]. - The company has issued $280.0 million of 4.00% convertible senior subordinated notes due 2025, with interest payable semi-annually[379]. - The company has never declared or paid any cash dividends on its common stock and does not intend to do so in the foreseeable future[394]. - The company's stock price has experienced significant volatility, which could impact its ability to raise capital[396]. Management and Operational Risks - The company is highly dependent on its senior management team, and the loss of key personnel could impede research and commercialization objectives[291]. - Employee misconduct or regulatory violations could significantly harm the company's business and reputation[316]. - The integration of Corstasis into the company's operations may present unforeseen difficulties and require significant management attention and financial resources[326]. - The company may face unknown liabilities or issues arising from the Corstasis acquisition that could adversely impact its business[325].

Core Insights - Esperion Therapeutics focuses on developing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) and aims to provide alternatives for those intolerant to statins [1] Financial Performance - For the quarter ending December 2025, Esperion reported earnings per share (EPS) of $0.21, slightly below the estimated $0.23, resulting in a negative surprise of 5.38% [2][6] - The company's revenue for the same quarter was $168.4 million, exceeding estimates of $166.1 million, and representing a 144% increase from $69.11 million in the same period last year [3][6] - For the fiscal year 2025, total revenue increased by 21% year-over-year to $403.1 million, with U.S. net product revenue rising by 38% year-over-year to $159.6 million [4] Market Position and Strategy - Esperion has announced an agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise, which includes the acquisition of Enbumyst, a bumetanide nasal spray [5][6] - Despite strategic advancements, the company faces challenges indicated by a negative enterprise value to operating cash flow ratio of -6.27, suggesting difficulties in generating positive cash flow [5]

Core Insights - Esperion Therapeutics (ESPR) reported that 2025 was a transformative year, showcasing the company's strongest performance to date [2] - The company emphasized its commitment to fortifying its financial foundation and enhancing commercial execution [2] Financial Performance - Esperion aims to target operating expenses of up to $255 million by 2026 while expanding its cardiometabolic portfolio [2] Strategic Initiatives - The acquisition of Corstasis is part of Esperion's Vision 2040, indicating a long-term strategy for growth and innovation in the cardiometabolic space [2]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $168.4 million, a 144% increase year-over-year [16] - U.S. net product revenue was $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [16] - Collaboration revenue surged to $124.7 million, a 232% increase compared to $37.6 million in Q4 2024, driven by a one-time payment of $90 million from Otsuka [16] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [15] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [7] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [7] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in Q4 royalty revenue compared to Q4 2024, expanding access to 30 countries [9] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced Vision 2040, outlining long-term ambitions and a roadmap for growth, including the acquisition of Corstasis Therapeutics [5] - The acquisition of Corstasis is expected to enhance the company's portfolio with Enbumyst, a first-in-class intranasal diuretic, and expand its presence in the cardiometabolic market [11][14] - The company aims to grow its two franchises to multi-billion-dollar potential [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [8] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to support the use of bempedoic acid [8] - The company anticipates significant growth opportunities in the heart failure market with the launch of Enbumyst [13] Other Important Information - The company plans to fully leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst [14] - The transaction for the acquisition of Corstasis is expected to close in Q2 2026 [14] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are ready for the launch and will provide updates on the auto-injector after the deal closes [22][25] Question: Updates on ACC guidelines - Management expects the guidelines to be released a week before the ACC conference and is preparing a cross-functional plan for the medical community [28][32] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the European guidelines have positively influenced U.S. prescribing and anticipates similar effects from the upcoming U.S. guidelines [39][44] Question: Triple combination products and market research - Management indicated high excitement for the triple combination therapy and clarified that it does not muddy the messaging around statin intolerance [61][62] Question: Corstasis clinical obligations and updates - There are minimal post-market obligations for Enbumyst, and management does not expect them to significantly impact operations [70] Question: Risks of concessions in 2026 - Management stated they do not foresee the need for concessions, emphasizing strong coverage and outcomes data [56]

Financial Data and Key Metrics Changes - The company reported total revenue of $168.4 million for Q4 2025, an increase of 144% year-over-year [16] - U.S. net product revenue reached $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [16] - Collaboration revenue surged to $124.7 million, a 232% increase compared to $37.6 million in Q4 2024, driven by a one-time payment of $90 million from Otsuka [16] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [15] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [7] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [7] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in fourth quarter royalty revenue compared to Q4 2024, expanding access to 30 countries [9] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced its Vision 2040 strategy, aiming for long-term growth and the acquisition of Corstasis Therapeutics to enhance its portfolio [5] - The acquisition of Corstasis is expected to provide global rights to Enbumyst, a first-in-class intranasal diuretic, expanding the company's presence in the cardiometabolic market [11][12] - The company plans to leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst and accelerate revenue contribution [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [8] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to positively impact the company's products [8] - Management emphasized the importance of the upcoming U.S. guidelines and their potential to enhance awareness and prescribing of bempedoic acid [35][44] Other Important Information - The company anticipates completing clinical and regulatory requirements for its triple combination programs by 2027 [8] - The planned acquisition of Corstasis is expected to close in Q2 2026, further strengthening the company's market position [14] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are prepared for the launch and have sufficient capacity for the product [23] Question: Updates on ACC guidelines - Management expects the guidelines to be released a week before the ACC conference and is preparing a comprehensive plan for the medical community [29][32] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the sentiment from U.S. physicians is positive regarding the European guidelines, which could lead to increased awareness and prescribing [42][44] Question: Triple combination product label expectations - Management indicated that the label for the triple combination will not carry outcomes data but will still be well-received by physicians [49] Question: Collaboration revenue guidance for 2026 - Management highlighted that collaboration revenue will be influenced by ongoing partnerships and the ramp-up of manufacturing [51] Question: Risks of additional concessions in 2026 - Management stated they do not foresee the need for concessions, as they have strong coverage and outcomes data to support their products [56]